Completed OBSERVATIONAL NCT04028479

The Registry of Oncology Outcomes Associated with Testing and Treatment (ROOT)

Sponsor: Taproot Health

Conditions Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adenocarcinoma Adenocystic Carcinoma Adrenal Cancer Anal Cancer Appendix Cancer Astrocytoma Bile Duct Cancer Bladder Cancer Bone Cancer Brain Stem Neoplasms Brain Tumor Breast Cancer CNS Cancer Cancer of Colon Cancer of Pancreas Cancer, Advanced Carcinoid Tumor Cervical Cancer Cholangiocarcinoma Chondrosarcoma Chronic Myeloid Leukemia Colon Cancer Colorectal Cancer Esophageal Cancer Esophagus Cancer Fallopian Tube Cancer Gestational Trophoblastic Tumor Glioblastoma Head and Neck Neoplasms Hepatic Cancer Kidney Cancer Larynx Cancer Liposarcoma Liver Cancer Lung Cancer Melanoma Mesothelioma Multiple Endocrine Neoplasia Multiple Myeloma Nasopharyngeal Carcinoma Neuroendocrine Tumors Non Hodgkin Lymphoma Osteosarcoma Ovarian Cancer Pancreatic Cancer Parathyroid Neoplasms Parotid Tumor Penile Cancer Pharynx Cancer Pheochromocytoma Prostate Cancer Pulmonary Carcinoma Rectal Cancer Renal Cell Carcinoma Salivary Gland Cancer Sarcoma Sarcoma, Kaposi Sarcoma,Soft Tissue Skin Cancer Small Bowel Cancer Small Cell Carcinoma Stomach Cancer Synovial Sarcoma Testicular Cancer Testis Cancer Thymus Cancer Thyroid Cancer Tongue Cancer Unknown Primary Tumors Ureter Cancer Uterine Cancer Vaginal Cancer Vulvar Cancer Waldenstrom Macroglobulinemia

Interventions Biomarker Testing (L) Patient Reported Outcomes (P) Systemic Treatment (T)

Updated 14 times since 2019 Last updated: Dec 13, 2024 Started: May 5, 2021 Primary completion: Oct 31, 2024 Completion: Oct 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, this trial is completed. The trial is conducted by Taproot Health and has accumulated 14 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

14 versions recorded

Jan 2025 — Present [monthly]

Completed

Status: Recruiting → Completed
Sep 2024 — Jan 2025 [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Dec 2023 — Jul 2024 [monthly]

Recruiting
Nov 2022 — Dec 2023 [monthly]

Recruiting

▶ Show 9 earlier versions

Dec 2021 — Nov 2022 [monthly]

Recruiting
Nov 2021 — Dec 2021 [monthly]

Recruiting

Status: Not Yet Recruiting → Recruiting
Apr 2021 — Nov 2021 [monthly]

Not Yet Recruiting
Jan 2021 — Apr 2021 [monthly]

Not Yet Recruiting
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting
Jun 2020 — Nov 2020 [monthly]

Not Yet Recruiting
Apr 2020 — Jun 2020 [monthly]

Not Yet Recruiting
Oct 2019 — Apr 2020 [monthly]

Not Yet Recruiting
Aug 2019 — Oct 2019 [monthly]

Not Yet Recruiting

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Taproot Health

Data source: Taproot Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Idaho Falls, United States
• Laredo, United States